Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Interventions: DRUG: KN026|DRUG: HB1801|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel
Sponsor: Shanghai JMT-Bio Inc.